Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) will present a poster at the International Association for the Study of Pain (IASP) 2026 World Congress on Pain, examining the effects of TONMYA (cyclobenzaprine HCl sublingual tablets) on fibromyalgia symptoms and physical function. The congress is scheduled for Oct. 26-30, 2026, in Bangkok, Thailand. The announcement signals the company's intent to showcase its flagship medicine to the global pain-research community and to build clinical evidence around a product that received U.S. Food and Drug Administration approval on Aug. 15, 2025, and was commercially launched in the United States on Nov. 17, 2025.
The presentation matters because TONMYA is the first new treatment for fibromyalgia in more than 15 years, according to the company. Fibromyalgia is a chronic condition characterized by widespread pain, fatigue and cognitive difficulties, and patients have long faced a limited set of therapeutic options. By bringing data on symptom relief and physical function to an international pain congress, Tonix is positioning TONMYA not only as a commercial product but as a subject of ongoing scientific scrutiny. The poster's focus on physical function is particularly relevant, as improvements in daily functioning are a key measure of real-world benefit for patients living with the disorder.
Tonix describes itself as a fully integrated, commercial-stage biopharmaceutical company focused on central nervous system and immunology treatments in areas of high unmet medical need. Its CNS commercial infrastructure supports marketed products including the acute migraine treatments Zembrace SymTouch and Tosymra. The company is also maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, its CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. The company notes that its product development candidates are investigational new drugs or biologics, and their efficacy and safety have not been established and have not been approved for any indication.
The IASP World Congress is a prominent forum for pain research, and presenting there can raise awareness among clinicians and researchers who treat fibromyalgia. For investors, the event offers a potential catalyst: data that reinforces TONMYA's clinical profile could support adoption and broaden the drug's positioning. The latest news and updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP. The full press release can be viewed at https://ibn.fm/jFHh3.
The announcement was distributed through TinyGems, a specialized communications platform focused on innovative small-cap and mid-cap companies. TinyGems is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire, editorial syndication to thousands of outlets, press release enhancement, social media distribution and tailored corporate communications solutions. Such distribution helps emerging companies reach investors, journalists and the public. Full terms of use and disclaimers applicable to all content provided by TinyGems are available at https://www.TinyGems.com/Disclaimer.
